Aquestive Therapeutics Valuation
| AQST Stock | USD 3.21 0.10 3.22% |
At this time, the firm appears to be undervalued. Aquestive Therapeutics shows a prevailing Real Value of $5.02 per share. The current price of the firm is $3.21. Our model approximates the value of Aquestive Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 98.87 M, return on asset of -0.24, and Operating Margin of (1.14) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Aquestive Therapeutics' valuation include:
Undervalued
Today
Please note that Aquestive Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Aquestive Therapeutics is based on 3 months time horizon. Increasing Aquestive Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Aquestive Therapeutics' intrinsic value may or may not be the same as its current market price of 3.21, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.21 | Real 5.02 | Target 10.83 | Hype 3.22 | Naive 3.61 |
The intrinsic value of Aquestive Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aquestive Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aquestive Therapeutics helps investors to forecast how Aquestive stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aquestive Therapeutics more accurately as focusing exclusively on Aquestive Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Aquestive Therapeutics' intrinsic value based on its ongoing forecasts of Aquestive Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Aquestive Therapeutics' closest peers.
Aquestive Therapeutics Cash |
|
Aquestive Valuation Trend
Aquestive Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Aquestive Therapeutics' financial worth over time. Using both Aquestive Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Aquestive Revenue by Product
Aquestive Therapeutics Total Value Analysis
Aquestive Therapeutics is presently projected to have valuation of 285.32 M with market capitalization of 317.38 M, debt of 38 M, and cash on hands of 17.7 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aquestive Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
285.32 M | 317.38 M | 38 M | 17.7 M |
Aquestive Therapeutics Investor Information
About 48.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.51. Aquestive Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Aquestive Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aquestive Therapeutics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Aquestive Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aquestive Therapeutics has an asset utilization ratio of 56.75 percent. This implies that the Company is making $0.57 for each dollar of assets. An increasing asset utilization means that Aquestive Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Aquestive Therapeutics Ownership Allocation
Aquestive Therapeutics holds a total of 98.87 Million outstanding shares. 30% of Aquestive Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Aquestive Therapeutics Profitability Analysis
The company reported the previous year's revenue of 57.56 M. Net Loss for the year was (44.14 M) with profit before overhead, payroll, taxes, and interest of 39.69 M.About Aquestive Therapeutics Valuation
The stock valuation mechanism determines Aquestive Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Aquestive Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aquestive Therapeutics. We calculate exposure to Aquestive Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aquestive Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 39.7 M | 33 M | |
| Pretax Profit Margin | (0.77) | (0.81) | |
| Operating Profit Margin | (0.53) | (0.56) | |
| Net Loss | (0.77) | (0.81) | |
| Gross Profit Margin | 0.69 | 0.73 |
Aquestive Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Aquestive Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 86.7 M |
Aquestive Therapeutics Current Valuation Indicators
Aquestive Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Aquestive Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aquestive Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aquestive Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aquestive Therapeutics' worth.Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.